Chronic lymphocytic leukemia: an enigma for both the clinician and the immunologist
Cristina Scielzo, Michela Frenquelli, Marta Muzio, Maria T.S. Bertilaccio Antonis Dagklis
Federico Caligaris-Cappio Paolo Ghia
Unit and Laboratory of Lymphoid Malignancies, Department of Oncology, Università Vita-Salute San Raffaele and Istituto Scientifico San Raffaele, Milano, Italy
Nevertheless, all this body of knowledge has not resulted in a parallel improvement in the management and treatment of CLL, which remains up to now an incurable disease. Somatic mutations though potent in predicting prognosis at cohort level, correlate with the clinical outcome and other biological prognostic markers in no more than 80% of the affected individuals, thereby hampering a real patient-tailored therapeutic approach.
All these reasons make mandatory to further study the biology of the disease and especially the IG receptor that appears to be pivotal in the onset and progression of the disease. This will be instrumental for the identification of the patient who needs a different treatment in terms of strategy and timing, for the design of biology based therapies and for patient-tailored therapeutic approaches.
